Sezary Syndrome
📧 Sign up to get email alerts when something new happens for Sezary Syndrome.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2013-01-24Clinical Trial Update: MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas [Phase 1]
This Phase 1 trial evaluated entinostat (MS-275) plus isotretinoin in adults with metastatic or advanced solid tumors or various lymphomas; …
-
CLINICAL_TRIALS trial_result · 2013-01-23Clinical Trial Update: 506U78 in Treating Patients With Recurrent or Refractory Cutaneous T-cell Lymphoma [Phase 2]
A Phase 2 trial evaluating 506U78 for recurrent or refractory cutaneous T-cell lymphoma has been terminated.
-
CLINICAL_TRIALS trial_result · 2013-01-16Clinical Trial Update: 506U78 in Treating Patients With Lymphoma [Phase 2]
Phase 2 clinical trial update on the agent 506U78 for various lymphomas; the study has completed.
-
CLINICAL_TRIALS trial_result · 2013-01-16Clinical Trial Update: Interleukin-12 and Interleukin-2 in Treating Patients With Mycosis Fungoides [Phase 1, Phase 2]
Phase 1/2 trial evaluating interleukin-12 and interleukin-2 in patients with mycosis fungoides and Sezary syndrome. The study was terminated…
-
CLINICAL_TRIALS research · 2012-08-22Clinical Trial Update: Killer Immunoglobulin-Like Receptor Transcripts Expression for the Diagnosis of Epidermotropic Cutaneous T Cell Lymphoma [NA]
The update discusses evaluating killer immunoglobulin-like receptor transcripts as a diagnostic approach for epidermotropic cutaneous T-cell…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2008-03-05Clinical Trial Update: Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients [Phase 4]
Phase 4 clinical trial update of ONTAK (denileukin diftitox) in patients with previously treated cutaneous T-cell lymphoma, including Mycosi…
-
FDA approval · 2006-10-06FDA Approved: ZOLINZA — Original Application (Merck Sharp & Dohme LLC)
The FDA approved Zolinza (vorinostat) under original NDA for cutaneous T-cell lymphoma, marking the first approval of this histone deacetyla…